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Respiratory infections caused by the opportunistic bacterial pathogen Pseudomonas 
aeruginosa are a common cause of mortality in patients with cystic fibrosis (CF). These 
infections are difficult to eradicate with conventional antibiotic treatment as P. 
aeruginosa is often innately resistant to many antibiotics. In clinical practice, diagnostic 
labs test P. aeruginosa strains in vitro (outside of a living organism) in order to determine 
an appropriate antibiotic to prescribe to each patient. However, these test results can be 
misleading because antibiotic resistance is highly dependent on the chemical environment 
in which the bacteria grow. Therefore, it is essential that in vitro models used to assess 
antibiotic resistance resemble in vivo growth conditions as closely as possible. In this 
thesis, I compared the antibiotic resistance of P. aeruginosa in two growth conditions: 
within a complex media commonly used in diagnostic labs, and a chemically defined 
synthetic sputum media (SCFM2) constructed to closely mimic the lung fluid of cystic 
fibrosis patients. I tested P. aeruginosa in both media, using three clinically relevant 
antibiotics (tobramycin, gentamicin, and polymyxin B), and found that the bacteria 
produce significantly different antimicrobial susceptibility profiles depending on the 
media in which they are cultured. Ultimately, the data presented here have the potential to 
help guide diagnostic labs to create more accurate in vitro models to predict more 
effective treatments for individual patients. 
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Background: Cystic Fibrosis 
What is Cystic Fibrosis 
Cystic Fibrosis (CF) is an autosomal recessive genetic disorder that affects many parts of 
the body. It is the most prevalent fatal genetic disorder in the United States (O’Sullivan et 
al., 2009), and it is thought to have arisen in Europe roughly 5000 years ago (Busch et al., 
1990). The disease can vary greatly in severity, though nearly all patients suffer from 
respiratory problems. These respiratory symptoms almost always result in bacterial 
infections of the lungs and airways (Govan et al., 2007), which can be extremely difficult 
to effectively treat through conventional antibiotic therapy. Because of this, the most 
common cause of mortality of CF patients is complications resulting from chronic 
bacterial lung infections. Therefore, advancements in CF research are often focused on 
understanding more about and improving treatments of these chronic infections. 
Cystic Fibrosis (CF) is an autosomal recessive genetic disorder caused by 
mutation of the cystic fibrosis transmembrane regulator (CFTR) gene (Sosnay et al., 
2016). “Autosomal” refers to the fact that the gene is on a non-sex chromosome, meaning 
that it is not carried on female X chromosomes or male Y chromosomes. “Recessive” 
means that a patient must have two mutant copies of the gene in order to have the disease. 
Generally speaking, sexual organisms have two alleles of every gene, one transmitted 
from the mother and one from the father. This means that CF patients must receive a 
mutation from both of their parents. However, since it is a recessive disorder, it is not 
uncommon for patients to have very few effected family members. 
 The mutation responsible for CF is thought to have originated in Europe, which is 
supported by both historical and scientific accounts . CF is most prevalent in people of 
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Northern European decent, and is the most common fatal genetic disorder in the United 
States, occurring once per every 3000 live births (O’Sullivan et al., 2009). However, the 
occurrence of CF in specific countries can vary. In Romania, for instance, 1 in every 
2000 babies is born with CF, and in Canada, 1 in every 2500 (Farrell et al., 2008). Other 
ethnic groups are also affected by CF, but to a lesser degree. It’s estimated that 1 in every 
4000-10,000 Latin American children, and 1 in every 15,000-20,000 African American 
children are born with CF (Macri et al., 1991; Phillips et al., 1995). The disorder is 
extremely rare in Africa and Asia, by contrast (Padoa et al., 1998; Singh et al., 2015). In 
Japan, for example, the reported rate of incidence is 1 in every 350,000 births (Yamashiro 
et al., 1997). In the United States, 1 in every 3000 babies are born with CF, and it is 
estimated that 1 in 25 Americans are carriers of the genetic mutation (O’Sullivan et al., 
2009). Men and women are affected by CF equally, though symptoms of reproductive 
organs are different between the sexes. 
 The name of the gene, CFTR, stands for “Cystic Fibrosis Transmembrane 
Conductance Regulator.” Like many genes, the name is an indicator of the gene’s 
function. The transmembrane conductance regulator is a protein found on cell membranes 
that functions as a chloride channel (Sosnay et al., 2016). It’s function is regulating the 
transport of chloride ions in and out of epithelial cells. A secondary function of this 
protein is inhibiting sodium transport from sodium channels. Therefore, mutations in this 
gene cause dysfunction in the transport of salt and fluids across cell membranes. One 
consequence of this is the presence of abnormally high levels of salt on the patient’s skin, 
which is one of the only symptoms of CF that can be detected without specialized testing 
(Gibson et al., 1959). Mutations in the CFTR gene cause a variety of symptoms, and a 
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wide array of organs can be affected (di Sant’Agnese et al., 1956; Kaplan et al., 1968). 
One of the milder symptoms of the disease is unusually high levels of salt in the patient’s 
sweat. Due to the harmlessness of the symptom and its relative ease of detection, salt 
levels in the sweat is now the main method that doctors use to diagnose CF. 
However, not all symptoms of the disease are benign. Many vital organs within 
the body—such as the lungs, pancreas, and the reproductive organs in males—are greatly 
impacted by the disorder (di Sant’Agnese et al., 1956; Kaplan et al., 1968). In males, 
abnormal secretions and fluid transport can cause complications in the development of 
the vas deferens, which is responsible for transporting sperm to ejaculatory ducts prior to 
ejaculation. This obstruction often leads to the absence of the vas deferens in male CF 
patients, leading to infertility in 97% of males (Chotirmall et al., 2009). This does not 
always leave male CF patients sterile, however, because sperm production is not always 
affected. As a result, some men with CF can have children through medical assistance. In 
other cases however, some men with CF do have a lack of sperm production or have 
abnormal sperm and are unable to have children. Infertility only effects 20% of women 
with CF. This infertility is often caused by thickened cervical mucus, or in rarer cases, 
malnutrition as a result of the disease (“Cystic Fibrosis Foundation: Reproductive Health 
and Fertility,” 2016). 
 Thickened mucus is a key symptom of CF. The thickened mucus is a direct result 
of fluid transport problems resulting from the aforementioned mutations in the CFTR 
gene. This mucus has a profound effect on pancreatic function, causing a variety of 
complications (di Sant’Agnese et al., 1956). The pancreas’ main function is producing 
and releasing digestive enzymes into the intestine to break down food after it has left the 
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stomach. Thickened secretions in and around the pancreas can obstruct pancreatic ducts, 
which is where these enzymes are released from the pancreas. In severe cases, these ducts 
can be completely clogged (di Sant'Agnese et al., 1956). In addition to damage to the 
pancreas, this also prevents food from being broken down after passing through the 
stomach. Since the enzymes are either absent or insufficient in number, the nutrients from 
food are not able to be extracted and absorbed through the intestines. This symptom, a 
condition known as meconium ileus, is one of the earliest signs of CF, occurring in 5-
10% of affected newborns (Mitchell et al., 2007). While this obstruction can be relieved 
using a variety of procedures, if untreated it can result in severe malnutrition, inability to 
pass feces, abdominal pain, and, eventually, death. 
 In modern cases of CF, however, complications of the lung are by far the most 
pressing concern. The thick secretions resulting from abnormal functioning of 
transmembrane conductance regulators causes a dramatic thickening of the mucus lining 
of the lungs (Lieberman et al., 1960). In healthy people, this mucus is thin and fluid. Its 
function is to trap bacteria and other potentially harmful particles in order to prevent lung 
damage and infection (Lillehoj et al., 2002). This mucus works in conjunction with cilia, 
tiny hair-like structures that sweep away particles trapped in the mucus, keeping the lungs 
and airways clear. In patients with CF, respiratory mucus, like other bodily secretions, is 
abnormally thick. While the mucus is still able to trap particles that enter the lung, the 
extreme thickness and viscosity makes it impossible for cilia to sweep the mucus—and 
the particles trapped within it—out of the lungs (Lieberman et al., 1960). As a result, the 
lungs of CF patients become increasingly filled with mucus, obstructing breathing and 
leading to violent fits of coughing. Other airways, such as the sinuses and trachea also 
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become clogged with respiratory mucus, with hinders breathing even further. Patients 
with CF must undergo regular therapies—often multiple times a day—to clear airways in 
order to retain breathing function (Bradley et al., 2005; Flume et al., 2009). 
 However, obstructing the patient’s ability to breathe is not the only complication 
that occurs inside the lungs of patients with CF. Since the lung cilia are unable to 
naturally clear the patient’s lungs, trapped bacteria begin to multiply very rapidly inside 
the lungs. Respiratory mucus, incidentally, provides a rich, nutritious medium for many 
bacteria to thrive. While physical airway clearance techniques help CF patients to expel 
lung mucus to a certain degree, clearing bacteria is a much more difficult task. As a 
result, nearly all patients with CF suffer from chronic lung infections. These infections 
are responsible for 80% of CF patient deaths, making chronic lung infections the leading 
cause of mortality (O’Sullivan et al., 2009). Because of this, modern CF research is 
centered around the prevention and treatment of chronic bacterial lung infections. 
 
 
The History of Cystic Fibrosis Research 
Although the disorder likely emerged as early as 3000 BCE (Busch, 1990), CF was not 
recognized by modern medicine until the mid-twentieth century (Andersen, 1938). 
However, recorded knowledge of the disorder can be found in various texts throughout 
human history, indicating that our ancestors recognized the symptoms of CF long before 
scientific evidence was able to corroborate.  
Prior to medical research on the disorder, children and infants with CF typically 
died of complications related to malfunctions of the pancreas, which is responsible for 
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secreting digestive enzymes into the small intestines to help break down food after it 
leaves the stomach (Busch, 1990). While CF does not directly alter or impair pancreatic 
function, it causes mucus to clog the organ and prevents the essential enzymes from 
entering the small intestine. As a result, no matter how nutritious their diet, patients with 
CF are unable to independently extract essential nutrients from food. As a result, before 
the advent of enzymatic treatments for CF, patients seldom survived infancy (Andersen, 
1938). 
The earliest recorded account of a patient dying from what is believed to be CF 
was by Professor Pieter Pauw in 1595. Pauw was a professor of botany and anatomy in 
Leiden, The Netherlands. He performed an autopsy on an eleven-year-old girl, who the 
locals described as “bewitched.” The girl appeared malnourished, and when Pauw 
examined her internal organs, he found that her pancreas was “swollen, hardened, 
gleaming white” (Quinton, 1999). He attributed this to steatorrhea, a symptom in which 
abnormal amounts of fats are found in the feces, indicating poor absorption of fat by the 
intestines. However, it wasn’t until 1905 that a physician named Karl Landsteiner showed 
definitive evidence that this symptom—among others—was characteristic of CF.  
There is also evidence that medieval Europeans recognized that unusually salty 
skin of children with CF. In this era, licking the foreheads of children and infants was a 
common practice in ritualistic cleaning ceremonies, which were conducted to counteract 
what were believed to be hexes (Quinton, 1999). If the child’s skin tasted salty, “the child 
was called bewitched or fascinated and was feared to die soon” (Busch et al., 1990). The 
salty skin of “bewitched” children was recorded across medieval Europe, in what are now 
12 different countries (Busch , 1990). The first scientific report of salty skin preceding 
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the death of a child was written in 1606 by Alonso y de los Ruyzes de Fonteca in 
Henares, Spain. However, it would take hundreds of years before physicians would 
realize that pancreatic and dermal symptoms resulted from the same disease. 
 Medical research concerning CF finally took off in the year 1938, when Dorothy 
Andersen, M.D., wrote a detailed report outlining the symptoms associated with CF. This 
report was based on the histories of 49 patients, and encompassed her personal 
observations and findings, as well as other cases documented in literature and by her 
colleagues. While pancreatic malfunction was her primary focus, she was the first 
researcher to correlate it with respiratory and intestinal symptoms (Andersen, 1938). 
Furthermore, she was able to demonstrate that enzymatic supplements were able to 
relieve the digestive ailments of her patients (Andersen, 1938). However, it soon became 
apparent that solving the digestive problems associated with CF was only the first of 
many hurdles that would challenge researchers in the subsequent decades.  
 In the years after Dorothy Andersen’s comprehensive report, the prognosis of CF 
patients steadily began to improve. While many digestive symptoms could be treated, 
children and infants instead died of respiratory complications resulting from abnormally 
thick mucus in the lungs (di Sant’Agnese et al., 1946). Subsequently, research was 
diverted to developing techniques to clear the patients’ airways to facilitate breathing. 
It was not until 1988—just before the explosion in research known as “the human 
genome project”—that Francis Collins, Lap-Chee Tsui, and John R. Riordan identified 
the first mutation associated with Cystic Fibrosis. One year later, in 1989, Lap-Chee Tsui 
and his team of researchers at the Hospital for Sick Children in Toronto discovered the 
gene that, when mutated, causes CF (Tsui et al., 1991). This is now known as the CFTR 
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gene, and since its discovery, over 1,700 different mutations have been identified in 
connection with CF (“Cystic Fibrosis Foundation: What is CF?”; Bobadilla et al., 2002).  
Once the CFTR gene was identified, along with over one thousand disease 
causing mutations, research has now focused on the treatment of respiratory infections of 
patients with CF. The life expectancy of CF patients has increased dramatically over the 
past century (Jerry A. Nick, M.D., “Cystic Fibrosis Life Expectancy”). In the late 30’s, 
children with CF hardly survived infancy. By the 1960’s, the life expectancy rose to ten 
years. As antibiotic therapies and airway clearance treatments advanced, the life 
expectancy of such patients increased to 15 years by 1970. This figure plateaued for 
about a decade and a half, however, until double lung transplants became a possibility. 
The first successful long-term double lung transplant on a CF patient was performed by a 
physician named Joel D. Cooper in 1988 (Pasque et al., 1990). After this, the average CF 
patient went from surviving until their mid to late teens, to surviving into their late 
twenties by 1990. Over the subsequent decades, advancements in antibiotic therapies and 
other techniques have steadily raised the life expectancy of CF patients to 37 years in the 
United States (Jerry A. Nick, M.D., “Cystic Fibrosis Life Expectancy”).  
 
 
 
 
Life with Cystic Fibrosis 
Cystic Fibrosis has a profound effect on a patient’s life from the very beginning. 
However, in modern times, the quality of life of CF patients is higher than it has ever 
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been. The first step to getting treatment for CF is a conclusive diagnosis. The vast 
majority of patients are diagnosed with CF during infancy or early childhood—typically 
before age 3. In the United States, roughly 66% of CF patients are diagnosed before their 
first birthday, and another 6% are diagnosed before their second birthday. In milder 
cases, some children do not exhibit symptoms of CF until later in childhood. About 20% 
of CF patients are diagnosed between the ages of 2 and 15. Only about 6% of CF cases 
are diagnosed after age 16 (“Cystic Fibrosis Foundation: Caring for a Child with CF,” 
2016). 
In order to diagnose CF, doctors perform a sweat test which determines the 
sodium and chloride levels in the patient’s sweat (Gibson et al., 1959). Elevated sodium 
and chloride levels in the perspiration of the patient, along with other CF symptoms, 
allows doctors to make a definitive diagnosis. The test is non-invasive, and doesn’t 
involve any injections. The test is begun by applying pilocarpine, an odorless, colorless 
chemical, to a small patch of skin on the patient’s arm to stimulate the sweat glands. A 
mild, painless electrical current is then applied to the arm for five minutes to further 
stimulate sweating. The sweat is then collected from with filter paper or gauze over the 
next 30 minutes. The sample is then sent to the diagnostic lab, where it is analyzed for 
elevated salt levels.  
After a positive diagnosis, children with CF must receive regular medical 
attention. Due to the complexity of the disease, patients must be treated for a variety of 
symptoms. CF patients must clear their airways twice daily, and there are a variety of 
ways that this can be done, though all methods involve some degree of coughing in order 
to rid the lungs of excess mucus (Flume et al., 2009) Many patients’ airway clearance 
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routine begins with the use bronchodilators—commonly known as inhalers—to widen the 
bronchi and relax the muscles around the airways. One common method used to clear 
airways is done by cupping the hand and clapping it on the patient’s back and chest. The 
patient sits in various positions to loosen mucus in different sections of the lungs. This 
procedure loosens up the mucus in the lungs so that the patient is able to cough it up 
(“Cystic Fibrosis Foundation: Airway Clearance Techniques,” 2016; Bradley et al., 
2006). After loosening the mucus and coughing it up, patients then take inhaled 
medicines through a nebulizer (Donaldson et al., 2006). These medicines include 
antibiotics in order to prevent bacterial infection.  
Like many other conditions, CF patients have to be very cautious about personal 
hygiene. CF patients are not immunocompromised, but the thick lung mucus leaves them 
extremely vulnerable to infection. Since these infections are often difficult or even 
impossible to eradicate using antibiotic therapies, preventing bacterial colonization on the 
airways is a key step in prolonging life expectancy and increasing quality of life (“Cystic 
Fibrosis Foundation: Caring for a Child with CF”). Children with CF may still attend 
school or daycare, but caregivers must be particularly cautious. It is important that CF 
children wash their hands regularly and avoid contact with individuals that may be sick. 
Proper nutrition is also essential to maintain the health of CF patients. Doctors 
encourage these patients, especially children, to receive high-fat, calorie-rich diets with 
plenty of vitamins and minerals (Ramsay et al., 1992). However, problems with 
pancreatic function often prevent the proper absorption of these nutrients, because the 
enzymes necessary to degrade food in the intestines are often absent or too few in number 
to work properly. As a result, CF patients must take pancreatic enzyme supplements with 
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every meal, including snacks, to ensure proper nutrition. Failure to do so can result in 
malnutrition and stunted growth (Bronstein et al., 1992).  
Through advancements in genetic research, it is believed that gene therapy could 
be used in the future to treat CF patients. Gene therapy would involve inserting correct 
(non-mutant) copies of the CFTR gene into the epithelial cells of patients (Burney et al., 
2012). The cells could then take up the correct genetic information and repair the 
transmembrane conductance regulator proteins on the cell membranes. The earliest 
attempt at gene therapy for CF patients occurred in 1993 (Collins et al., 1993), which 
used viral and non-viral gene transfer agents to insert the genetic information into the 
cells. This trial was unfortunately unsuccessful, but further research is ongoing into the 
potential efficacy of gene therapy. One of the main hurdles that researchers must face is 
that since CF is a lifelong disease, the epithelial cells are continuously being turned over 
and replaced with new cells—a normal part of everyday life. However, maintaining the 
corrective genetic sequence as the cells are continuously replaced is a problem that 
researchers have still not been able to solve. 
Although CF patients are living many years longer than they have in the past, 
chronic infections are still the major concern for modern CF healthcare. While the initial 
stages of the infection are typically manageable with antibiotic therapy, eventually the 
treatment’s effectiveness will begin to decline. Once antibiotic treatment stops being 
effective, CF patients must have a double lung transplant (Yankaskas et al., 1998). 
However, there are far more patients who need new lungs than there are available lungs 
for transplant (Saidi et al., 2014). Another complication is that CF patients must receive 
two new lungs—a single lung transplant is not enough. If only one lung is transplanted, 
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the infection will persist in the original lung and infect the new lung as well (Shennib et 
al., 1992). Donated lungs are given to patients based on need, so patients who are in the 
later stages of infection are given priority. Unfortunately, many patients die on the list 
awaiting transplant, because there are simply not enough donated lungs to accommodate 
all the patients on the list. 
Fortunately, due to advancements in physical and antibiotic therapies, CF patients 
in the 21st century are able to lead longer, healthier lives. With proper care and 
management of symptoms, CF patients are able to attend college, get married, and even 
have children. The fact still remains, however, that the average CF patient in the United 
States suffers from chronic lung infections. In the later stages, these infections can be 
debilitating, and the average life expectancy in the United States is only 37 years (“Cystic 
Fibrosis Foundation: Life with CF,” 2016). It is therefore imperative that more effective 
treatments for these infections be developed to increase the quality of life and life 
expectancy of these patients. 
 
 
 
 
 
 
Background: Pseudomonas aeruginosa 
What is Pseudomonas aeruginosa? 
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Pseudomonas aeruginosa is the major bacterial pathogen that affects patients with CF. It 
is classified as a Gram-negative bacteria, which is a common method of differentiating 
species of bacteria. Gram staining is performed by adding a crystal violet dye that can 
stain peptidoglycan—a polymer that surrounds the cell membranes of certain species of 
bacteria. Gram-negative bacteria are characterized by having an inner cytoplasmic 
membrane as well as an outer membrane, with a thin layer of peptidoglycan in between. 
Gram-positive bacteria, on the other hand, lack the outer membrane and instead have a 
thicker layer of peptidoglycan surrounding the cell. These morphological differences are 
used for identification of the species, as well as for determining effective treatments in 
the case of infection (Hucker et al., 1929). 
 P. aeruginosa is a rod-shaped bacterium typically 0.5 - 0.8 µm by 1.5 - 3.0 µm in 
size that is motile by means of one or two flagella (Schniederberend et al., 2013). It has a 
distinct sweet, earthy odor, and can be easily recognized by its often bright blue-green 
color. This color is the result of pyocyanin, a toxin produced by P. aeruginosa in order to 
kill other species of bacteria nearby. While it is not highly toxic to macro organisms, 
there is evidence suggesting that pyocyanin plays a role in the persistence of infections 
(Lau et al., 2004). 
 Additionally, P. aeruginosa is an opportunistic pathogen, meaning that it can live 
outside of the human body in addition to causing infection (Govan et al., 2007). In 
contrast, many bacteria that are well known for causing disease in humans are obligate 
pathogens. This means that in order to survive they must exist within a host, which 
causes infection. One example of an obligate pathogen is Mycobacterium tuberculosis, 
the bacteria that causes tuberculosis (Forrelland et al., 2013). Obligate pathogens cannot 
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survive outside of a host, meaning that they are not typically isolated from environments 
other than the human body. This means that in order to contract an opportunistic 
pathogen, a patient must come in contact with an infected individual.  
Opportunistic pathogens operate very differently, however, and can be contracted 
from a wide variety of sources. Pseudomonas aeruginosa is also an opportunist, though it 
is not known to frequently infect healthy individuals. Instead, P. aeruginosa typically 
infects vulnerable people, such as patients with weakened immune systems, open 
wounds, or CF (Friedrich et al., 2016). In addition, P. aeruginosa is also known to infect 
a wide range of organisms, including plants and animals (Emerson et al., 2002; Rahme et 
al., 1995).  
One distinguishing factor of P. aeruginosa is its relatively large genome size. P. 
aeruginosa has a genome size between 5.8-6.8 million base pairs and over 5,000 genes 
(Stover et al., 2000). For comparison, E. coli has about 4.5 million base pairs and 4,000 
genes. The large genome size of P. aeruginosa offers some explanation regarding the 
astounding variety of stimuli that the bacterium is able to respond to. This can be clearly 
demonstrated by the sheer number of environmental niches that P. aeruginosa can 
occupy. This organism has been isolated from soil, water, plants, humans, insects and 
other invertebrates (Corby-Harris et al., 2006; Emerson et al., 2002; Rahme et al., 1995). 
It is also very tolerant to a wide temperature gradient, and exhibits normal growth 
between 25 and 42 degrees Celsius (Tsuji et al., 1982). 
Biofilm formation is another hallmark of P. aeruginosa, which can be observed in 
both infections and in nature. A biofilm is formed by clusters of cells that stick together 
and adhere to a surface. Biofilms containing P. aeruginosa can be found in many 
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different habitats, such as plant roots, the human body, and household plumbing (Walker 
et al., 2003; Moritz et al., 2010).This group of cells is typically surrounded by 
extracellular polymeric substance (EPS), which gives biofilms their characteristic slimy 
appearance. Cells in biofilms behave remarkably different from planktonic (free-living) 
cells both phenotypically and physically, for example, biofilms can exist as complex 
three dimensional structure in response to a variety of environmental factors.  
Biofilm formation is also crucial for another behavior that this species exhibits. P. 
aeruginosa can form biofilms of varying sizes, including microscopic aggregates and 
biofilms that are visible to the naked eye (Rasamiravaka et al., 2015). When the cell 
density of P. aeruginosa aggregates reaches a certain threshold, the species is known to 
utilize a form of cell-to-cell communication known as quorum sensing (QS) (Wagner & 
Iglewski, 2008). This is an extremely basic form of communication used by some 
bacteria and insects in order to coordinate group behavior to benefit the survival of the 
community. Organisms with QS ability release signaling molecules in response to certain 
stimuli, which are received and interpreted by other individuals in the vicinity. It is 
known that at certain population density levels, P. aeruginosa uses QS to coordinate the 
upregulation or downregulation of certain genes throughout the local population. The 
regulation of these genes results in coordinated group responses to potential threats, 
which helps the population to persist (Whiteley et al., 2001; Wagner & Iglewski, 2008). 
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Pseudomonas aeruginosa Pathogenicity 
In addition to being able to occupy a wide array of niches, P. aeruginosa is also known 
for its ability to cause infections in a variety of organisms. Plants, invertebrates, and other 
animals—including humans—are all potential targets (Corby-Harris et al., 2006; 
Emerson et al., 2002; Rahme et al., 1995). P. aeruginosa has also shown a striking ability 
to retaliate its host’s defense systems by altering its spatial organization and gene 
regulation (Wagner & Iglewski, 2008; Rasamiravaka et al., 2015). While P. aeruginosa is 
not particularly virulent towards healthy organisms, once it secures a foothold within a 
host, it can be almost impossible to eradicate (Al-Aloul et al., 2004; Hart & Winstanley, 
2002). 
Studies have shown that under certain conditions, P. aeruginosa occupying soil 
habitats are able to infect plants by colonizing the roots. A study conducted in 2004 
showed that P. aeruginosa is able to infect Arabidopsis—a model organism used by plant 
biologists—and sweet basil both in vivo and in vitro (Walker et al., 2003). In response to 
the contact with pathogenic P. aeruginosa, basil plants secrete antibacterial compounds 
from their roots. Although the secretions are toxic to planktonic cells, the study found 
that P. aeruginosa was almost completely unaffected by this compound. Instead of being 
killed off by the toxin, P. aeruginosa responded by reverting from its planktonic form 
into a biofilm before the concentrations of the toxins were able to reach lethal levels. The 
basil plant’s attacks were unable to penetrate this biofilm, and both plants—basil and 
Arabidopsis—succumbed to the infection.  
 While plant infections do not directly relate to human health, the observations 
from the aforementioned experiment are somewhat analogous to how P. aeruginosa 
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behaves in human infections. P. aeruginosa is notorious for infecting humans in handful 
of specific circumstances. It has been known to colonize the urinary tract, airways, 
wounds, and medical devices (Pavlovskis & Wretlind, 1979; Bodey et al., 1983). Of these 
types of infections, the most common—and most problematic—are chronic infections of 
burn wounds and the lungs of CF patients.  
 Chronic bacterial lung infection is by far the leading cause of mortality among CF 
patients, and P. aeruginosa is one of the mostly isolated pathogens. It is estimated that 
between 70-80% of adults with CF have chronic lung infections, and 98% of these 
patients will be colonized with P. aeruginosa within 3 years of the initial infection 
(Govan et al., 2007). Compared to other pathogens, P. aeruginosa grows fairly slowly, so 
patients may not experience symptoms for some time after the initial colonization. In 
fact, most adults who test positive for the presence of P. aeruginosa in their lungs are 
believed to have initially contracted the bacteria in their childhood or teens (Gibson et al., 
2003).  
 At the early stages of P. aeruginosa infection, CF patients are typically colonized 
by a number of different strains, though over the course of the infection, one strain tends 
to dominate (Govan et al., 2007). However, these strains do not remain unchanged over 
time. P. aeruginosa is known for its ability to mutate readily in order to adapt to stressful 
environmental factors, including antibiotics. Unlike many other bacterial species, P. 
aeruginosa does not need to rely on spontaneous mutations to alter its genome. Instead, 
P. aeruginosa is able to undergo recombination, the process by which individuals are 
able to exchange DNA. For most macro organisms—which usually have two parents—
recombination is used to shuffle parental genes in order to produce genetically unique 
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progeny. Asexual organisms, by contrast, typically produce offspring that are genetically 
identical to their parents. Therefore, in order to evolve, many of these organisms must 
wait for a beneficial mutation to spontaneously arise. In P. aeruginosa, however, 
recombination is the driving force for diversity (Darch et al., 2015), allowing it to evolve 
rapidly and efficiently. 
 The highly mutable nature of P. aeruginosa has very serious implications for 
hospitals caring for CF patients. The ubiquitous nature of the organism means that it can 
be inadvertently spread between hospital patients through many vectors, including water, 
surfaces, and medical instruments. Since individuals tend to harbor unique, often highly 
resistant strains of P. aeruginosa, transmission of these strains between CF patients can 
have disastrous consequences. One example of such an event is the spread of the 
“Liverpool Epidemic Strain” in a children’s CF clinic in the mid 1990’s (Cheng et al., 
1996). The strain was resistant to ceftazidime, azlocillin, and imipenem, and was shown 
to be present in 55 of the 65 children at the clinic.  
 CF patients can contract P. aeruginosa in a number of ways, due to the ubiquitous 
nature of the organism. In most cases, P. aeruginosa is believed to be contracted from the 
environment. P. aeruginosa can grow in two different forms—mucoid and colonial—and 
each form has different implications for the patient. During early colonization, P. 
aeruginosa typically grows in colonial form, meaning that bacterial colonies resemble 
circular pinpricks, and look “dry” in appearance (Burns et al., 2001). This form tends to 
be fairly susceptible to antibiotics (Parviz et al., 2014) so with immediate, aggressive 
treatment, it is possible to eradicate from the lungs (Frederiksen et al., 1997). This 
immediacy of this treatment cannot be overstated, as P. aeruginosa can rapidly change its 
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phenotype in the presence of antibiotics (Oliver et al., 2000). This is very similar to the 
aforementioned experiment involving basil plants. While the plants are capable of 
producing enough of the defensive toxin to completely kill planktonic PA, this process 
does not happen fast enough to kill the bacteria before they develop resistance (Walker et 
al., 2003). Therefore, appropriate antibiotics must be administered to infected CF patients 
quickly and at a high enough concentration to completely kill the pathogen. However, 
patients often do not exhibit symptoms when the bacteria are in this stage of growth, so 
the presence of P. aeruginosa is typically not detected until it has developed the mucoid 
phenotype .  
 As the name suggests, the mucoid phenotype indicates a mucus-like appearance 
of bacterial growth. Mucoid growth tends to be irregularly shaped and appear wetter than 
colonial growth. The mucoid phenotype is associated with a heightened ability to form 
biofilms (Kenna et al., 2007). Biofilm formation is beneficial to P. aeruginosa not only 
because it makes bacteria less susceptible to antibiotics, but also because the high density 
of cells facilitates quorum sensing, which allows the bacteria to respond to changes in the 
environment collectively (Wagner & Iglewski, 2008).  
 
Diagnostic Techniques 
When a CF patient exhibits symptoms consistent with bacterial lung infection, it is 
imperative that he or she get immediate treatment to prevent chronic infection. In order to 
determine the ideal treatment, doctors must first determine which pathogen is responsible 
and which antibiotic to prescribe. Selecting the most effective antibiotic is especially 
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difficult if the pathogen is determined as P. aeruginosa, because different strains of this 
species can have extremely varied responses to different antibiotics (Kenna et al., 2007).  
 In order to select the appropriate antibiotic for each patients, diagnostic labs 
perform a test known as a disk diffusion assay (Bauer, 1959; Bauer & Kirby et al., 1966). 
The first step of this assay is to obtain a sample of lung mucus (formally referred to as 
“sputum”) from the patient. The patient—using aforementioned techniques—coughs up 
infected sputum, which is collected and sent to the lab. There, the sample is analyzed to 
determine which species are present. This is done in a variety of ways, such as 
monitoring growth rate, observing distinctive morphological and metabolic 
characteristics, and using selective media to isolate specific species (Washington, Chapter 
10). Due to its distinctive sweet, earthy smell and blue-green coloration, P. aeruginosa is 
not difficult to identify. Additionally, because of its prevalence among CF patients, 
diagnosticians frequently look for its presence in the lung sputum. 
 Once P. aeruginosa is isolated from the sample, the bacteria are grown in a Petri 
dish on nutritionally rich, non-selective media (Bauer, 1959; Bauer & Kirby et al., 1966). 
MHA is a common media used by diagnostic labs to test P. aeruginosa, as it is highly 
rich in nutrients and facilitates rapid bacterial growth. The bacteria are swabbed over the 
entirety of the agar surface, creating what is called a “bacterial lawn.” Afterwards, the lab 
technicians apply paper disks soaked with different antibiotics to the Petri dish. The 
disks—typically only one centimeter in diameter—are spaced apart from each other so 
that no cells are exposed to more than one antibiotic at a time. The antibiotics from these 
disks then diffuse into the agar over night as the bacteria grow. If the strain of P. 
aeruginosa is susceptible to the antibiotic, a zone of inhibition—areas that lack bacterial 
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growth—will be visible on the plate surrounding the antibiotic. The diameter of this kill 
zone directly relates to how susceptible the strain is to the antibiotic. From this test, 
doctors are able to determine what is known as the antimicrobial susceptibility profile 
(the level of susceptibility or resistance of the strain to different antimicrobial agents) of 
each patient’s particular strain of P. aeruginosa. 
 While this assay works well for many pathogens, this is unfortunately seldom the 
case for P. aeruginosa. Doctors may request that this test be done for the sake of 
following procedure, but most are aware that the susceptibility profiles produces are 
typically not indicative of how a patient will respond to the treatment. Instead, doctors 
often rely on their past experiences in treating P. aeruginosa, and prescribe antibiotics 
according to what they know about the species. Doctors also look at antibiotics that their 
patient has taken in the past, which can indicate what the strain has previously been 
exposed to—and therefore— competitors—and grows under relatively little stress. 
Furthermore, the media used by diagnostic labs is what it may have developed resistance 
to. 
 When one takes into account the plasticity and adaptability of P. aeruginosa, it 
becomes clear why this test produces such erroneous results. This species is known for its 
ability to thrive in a wide range of environments, which can be attributed, in part, to its 
relatively large genome (Stover et al., 2000; Corby-Harris et al., 2006; Emerson et al., 
2002; Rahme et al., 1995). When P. aeruginosa encounters a new habitat, it is able to 
change its behavior accordingly through both mutation and altered gene expression. The 
nutritionally rich media used by diagnostic labs does not resemble the conditions of a 
human CF lung in any way. On the rich media, P. aeruginosa has few obstacles to adjust 
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to—such as host immune response and bacterial competitors—and grows under relatively 
little stress. Furthermore, the media used by diagnostic labs is more nutritious than CF 
lung sputum, which further alters the behavior of the bacteria. Although the strain may 
exhibit sensitivity to an antibiotic in this in vitro model, this behavior cannot be 
correlated to how it will behave inside of a human lung. This is the microscopic 
equivalent of trying to learn about orca whale hunting techniques by observing orcas at 
sea world, or trying to learn about lion behavior by observing one in a hotel room. In 
order to get an accurate picture of an organism, the in vitro model must recapitulate the in 
vivo as closely as possible. 
 It is undeniable that prescribing the correct antibiotics to a CF patient is critical 
for preventing chronic infection and prolonging life expectancy. As such, making 
improvements to diagnostic testing of P. aeruginosa is absolutely vital. In my thesis, I 
propose that a modifications to the current diagnostic method in order to more closely 
emulate the in vivo in a clinical setting. In my experiments, I compared the responses of 
10 different strains of P. aeruginosa in two different types of growth media. The first 
media, Mueller-Hinton, is a rich media commonly used in diagnostic labs to test obtain 
the antimicrobial susceptibility profile of P. aeruginosa. The second media is called 
Synthetic Cystic Fibrosis Media 2 (SCFM2), which is a chemically defined media that 
has similar physical and nutritional properties to CF lung sputum.  
 These strains of P. aeruginosa were analyzed using minimum inhibitory 
concentration assays (MIC) in liquid media and disk diffusion assays on solid media. 
These assays were performed in the artificial sputum media and in the MH media. The 
data from these experiments was analyzed to generate antimicrobial susceptibility 
26 
 
profiles of each strain in each type of media, in order to see if the cells responded to 
antibiotics differently depending on the environment in which they are grown. The results 
indicated that all ten strains of P. aeruginosa exhibited varying levels of resistance and 
susceptibility to three clinically relevant antibiotics depending on the medium the cells 
were tested in. 
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Section Two: Materials and Methods 
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MIC Light Assay Protocol 
The minimum inhibitory concentration assay (MIC) was performed using a 96 well plate, 
Luminoskan Ascent microplate luminometer, and 3 clinically relevant antibiotics: 
polymyxin B, tobramycin sulfate, and gentamicin. Antibiotics were dissolved in 
nanopure water, filter sterilized, and stored, covered with aluminum foil, at 4°C. The 
selected medium—SCFM2 or Mueller-Hinton Broth (MHB) was then inoculated with P. 
aeruginosa strains carrying the luminescence reporter plasmid pQF50- lux (Murray et al., 
2015) standardized to an OD600 of 0.05 after washing cells twice in phosphate buffered 
saline (PBS). 200μL of inoculated media was added to the wells in the third column, and 
100μL of sterile media was added to the first column as positive and negative controls 
respectively. The remainder of the wells were filled with 100 μL of inoculated media. 
Antibiotics were added to the wells third column and then serially diluted two-fold across 
the wells, producing an antibiotic concentration gradient ranging from 2.5mg/ml to 
0.005mg/ml. The 96 well plate was then inserted into the Luminoskan Ascent microplate 
luminometer. The luminometer measured luminescence at 0 minutes, 30 minutes, and 60 
minutes from each of the 96 wells.  
 For this assay, luminescence is a proxy for cell viability. The levels of 
luminescence for each well treated with antibiotics were compared to wells that did not 
receive antibiotics. Results are presented as a percentage of cell viability for each well. In 
other words, a percentage of the bacterial population that survived the antibiotic. This 
assay was replicated three times for each strain. 
29 
 
Disk Diffusion Protocol 
The disk diffusion assays were performed using agar plates and antibiotic disks. These 
disks are circular pieces of paper, 1 cm in diameter, that contain 10 micrograms of 
antibiotic. The antibiotics used in this assay were tobramycin, gentamicin, and colistin 
sulfate (also known as polymyxin E). All agar plates contained 15ml of either SCFM2 or 
MHB agar. Prior to adding bacteria, plates were dried for 30 minutes in a biological 
cabinet. The day before the assay, bacterial strains to be tested were isolated onto LB 
agar plates, wrapped in aluminum foil, and allowed to grow overnight at 37°C.  
 On the day the assay is performed, 3 distinct colonies from each strain were 
selected. Each colony was inoculated into 1ml of sterile, nanopure water. The inoculated 
water was then streaked across the dry agar plates using a sterile cotton swab, ensuring 
that the entire surface of the agar is coated. Using small tweezers, one disk of each 
antibiotic was added to each plate (tweezers are rinsed with 70% ethanol and passed 
through a flame after each placement to prevent contamination). Plates were then 
inverted, wrapped in aluminum foil, and allowed to grow overnight at 37°C. Exactly 24 
hours after the disks were applied, the diameter of the zones of inhibition around each 
antibiotic disk were measured. This assay was replicated three times for each individual 
strain. 
 
Media Construction, Design and Composition 
Mueller-Hinton broth, Muller-Hinton agar 
Mueller-Hinton media is a rich, general purpose bacterial growth media. The brand used 
in these experiments was BD (Becton, Dickinson and Company) brand. The formula 
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contains 3.0g beef extract, 17.5g acid hydrolysate of casein, and 1.5g of starch per liter. 
For solid Mueller-Hinton media, agar was added at a concentration of 1% weight per 
volume. Media is autoclaved at 121°C at a pressure of 15psi for 20 minutes. 15mL of 
solid Mueller-Hinton media is added to Petri dishes by pipetting. Media is stored at 4°C. 
Synthetic cystic fibrosis sputum media (SCFM2) 
SCFM2 is comprised of four main components: A buffered base containing essential 
amino acids and salts, DNA, mucin, and the lipid 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC).  
DNA purification 
The DNA in this medium is derived from salmon sperm, and must be purified before 
being added to the media. 250 milligrams of dehydrated salmon sperm is dissolved in di-
water at a concentration of 1 milligram of DNA per 1 milliliter of di-water. It takes 
roughly two hours for the DNA to completely dissolved. The solution is aliquoted into 
50mL conicals. An equal volume of cold (4°C) phenol-chloroform (PCL) is added to 
each conical. The conicals are then placed into a centrifuge that has been cooled to 4°C. 
The tubes are spun at 5000xg for 10 minutes. The solution will separate into 2 phases. 
The top phase is pipetted out and transferred to a fresh conical. 0.1 volumes of NaOAc at 
pH 5.2 is then added to each conical. 2 volumes of cold 100% ethanol are added to each 
conical. The conicals are then covered with aluminum foil and stored at -20°C for a 
minimum of 2 hours.  
 After incubation, the conicals are centrifuged at 4°C at 5000xg for 30 minutes. 
The DNA will pellet at the bottom on the conical. The supernatant is then removed from 
the conical and 1 volume of cold 70% is added. The solutions are placed back into the 
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4°C centrifuge at 5000xg for 10 minutes. The supernatant is removed, and another 
volume of cold 70% ethanol is added. The solutions are centrifuged at 4°C at 5000xg for 
10 minutes. The supernatant is removed again, and the tubes are placed, uncovered, in a 
chemical hood to dry overnight. Once the pellets are completely dry, the pellets are 
removed from the conicals with tweezers and placed in Petri dishes. The pellets are 
weighed, and then placed, uncovered, in a UV sterilization drawer for 30 minutes. The 
Petri dishes are then removed, wrapped in parafilm and aluminum foil, and stored at -
20°C. 
Porcine Mucin 
250mg of dehydrated mucin is weighed out into Petri dishes and placed, uncovered, into 
the UV sterilization drawer. The mucin is sterilized for 4 hours, mixing once every 30 
minutes. Mixing is done by replacing the lid and gently shaking the Petri dish. The lid is 
then removed again and left in the UV drawer. Mucin is then stored at -20°C for future 
use. 
Buffered Base 
There are 34 individual liquid stocks that are combined when making the buffered base. 
These stocks include but are not limited to 19 amino acids, salts, and MOPS. Stocks are 
made by dissolving solids in nanopure water and then filtering sterilizing. All stocks are 
stored at 4°C, covered with aluminum foil, for up to two weeks. Appropriate amounts of 
the stocks are then added to 190mL of nanopure water, mixed, and filtered sterilized.  
 
SCFM2 Construction 
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The media is made by combining appropriate amounts of mucin, DNA, and the buffered 
base. Upon addition of sterilized DNA and mucin, the lipid 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) is added at a concentration of 100ug/mL. DOPC is first 
dissolved in chloroform at a concentration of 250mg/ml, however, in order to allow it to 
better dissolve into the buffered base. The media is then placed in an incubator at 37°C 
for one hour, shaking at 250rpm to evaporate chloroform. The SCFM2 media is stored at 
4°C for up to two weeks.  
SCFM 2 agar 
The solid version of the SCFM2 media is prepared in a similar fashion to the liquid 
media. However, the buffered base is made twice as concentrated (2 times the amount of 
stocks added to the original volume of nanopure water). Twice the amount of DNA and 
mucin is also added. In another flask, nanopure water is added at a volume equal to the 
concentrated buffered base. Agar is added to the nanopure water at a concentration of 2% 
of the total volume of water, which is equivalent to 1% of the buffered base and water 
when combined. The agar solution is well mixed and autoclaved at 121°C at a pressure of 
15psi for 20 minutes to sterilize.  
 Once the chloroform from the added DOPC solution has been evaporated from 
the buffered base and the agar solution has been autoclaved, both flasks are placed into a 
50°C water bath for one hour, or until the temperatures of both solutions are equivalent. 
Working aseptically, the buffered base is pipetted into the agar solution 50mL at a time. 
Using the stir bar that remained in the agar flask in the autoclave, the solutions are mixed 
together for 5 minutes, or until the solution is homogenous. The solution is pipetted into 
Petri dishes in 15mL aliquots. 
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Strains: Origins and Significance 
PAO1 
PAO1 is the most common strain of Pseudomonas aeruginosa used in laboratory research 
that exhibits the colonial (non-mucoid) phenotype. It is a wild-type strain of P. 
aeruginosa, meaning that its genotype is the natural (non-mutant) form of the species. 
Because of this, PAO1 is commonly used as a control—or “reference”—strain. It is 
derived from an initial isolate called PAO. This strain was isolated from a patient in 
Australia by B.W. Holloway in 1955. Since then, the strain and its variants have been 
distributed to labs worldwide to be used in experimental research (Klockgether et al., 
2010). The strain of PAO1 used in these experiments carried plasmid pQF50-lux. This 
gene on this plasmid contains a luminescence expressing gene, with causes living cells to 
produce light. 
PA14 
This strain of P. aeruginosa is another common strain used in laboratory research that, 
like PAO1, has the colonial phenotype. PA14 is considered more virulent than PAO1, as 
it carries pathogenicity islands not present in the P. aeruginosa core wild-type genome 
(He et al., 2004). While this research project is only concerned with impacts on human 
health, it is worth noting that PA14 is able to colonize both plants and animals. In these 
experiments, PA14 carried plasmid pQF50-lux, which causes living cells to produce 
light. 
SED4, SED6, SED9, SED20, SED21 
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These five strains are clinical isolates, as opposed to lab or wild-type strains. These 
isolates were provided in collaboration with Nottingham University Hospitals NHS trust. 
The samples were isolated from sputum samples obtained from a 19 year old female with 
CF, who had been chronically infected with P. aeruginosa for 3 years. At the time when 
the samples were collected, the patient was in stable condition and was prescribed 
maintenance oral and nebulized therapies (Darch et al., 2015). The morphological 
characteristics between these strains are relatively consistent—all produce observable 
amounts of pyocyanin and grow in colonies. These strains were selected for this study via 
a random number generator. 
C2773C, C1913C, C3881C 
These 3 strains are clinical isolates collected from 3 different CF patients. These patients 
were at British Columbia’s Children’s Hospital, Shaughnessy Hospital, or St. Paul’s 
Hospital in Vancouver, British Columbia, Canada. The isolates were obtained from either 
lung sputum or throat samples (Huse et al., 2010). Unlike the other set of clinical isolates, 
these strains were isolated from separate patients, are mucoid, and produce lower levels 
of pyocyanin in comparison. These strains were selected for this study via a random 
number generator. 
Plasmid Transformation of Clinical Strains 
In order to perform minimum inhibitory concentration assays (MIC) on these strains, all 
were transformed with plasmid pQF50-lux via electroporation. To do this, cells were first 
grown in 5mL of LB at 37°C shaking at 250rpm. These strains have longer doubling 
times than PAO1 and PA14, therefore cells were grown for 36-48 hours. Cells were then 
removed from the incubator, and 200mL of each culture were added to 5mL of fresh LB 
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media. Cells were grown in the incubator for an additional 1.5 hours at 42°C, so that cells 
could reach the exponential stage of growth.  
Cells were then removed from the shaker and placed on ice for 10 minutes. All 
cultures were then transferred to 15mL conicals and spun in a 4°C centrifuge at 5000xg 
for 4 minutes. Since the cells then form pellets at the bottom of the tubes, the media can 
then be poured out and disposed of. To wash the cells, 5mL of cold 300mM sucrose 
solution was added to each culture, and pipetted until the cells were resuspended. Cells 
were spun in the 4°C centrifuge at 500xg for 4 minutes, and the supernatant was poured 
off. Cells were washed 2-3 times. After pouring off the supernatant a final time, 50 μL of 
cold 300mM sucrose solution was added to each conical. 5 μL of the plasmid DNA is 
then added to each strain. The cells were pipetted until resuspended, transferred to chilled 
cuvettes, and then placed into the electroporator. A electrical current of 2500V is applied, 
which causes the bacteria to uptake the plasmid. 1mL of fresh LB media is added into the 
cuvette, mixed thoroughly, and transferred into a fresh Eppendorf tube. Strains are then 
placed into the incubator at 37°C shaking at 250rpm. Cells are allowed to grow for at 
least 1 hour.  
After incubation, the strains are removed from the incubator and transferred to LB 
agar plates containing the antibiotic carbenicillin. In addition to the lux gene, this plasmid 
also contains a carbenicillin resistance gene, meaning that cells that correctly took up the 
plasmid will also be resistant to this antibiotic. Cultures are inoculated onto these plates, 
wrapped in aluminum foil, and incubated statically at 37°C for 36-48 hours. Cells that 
grow on the antibiotic-LB plates are then examined under UV light so that luminescence, 
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if present, can be seen. Cells can also be inserted into the Luminoskan Ascent microplate 
luminometer—which measures light—to check for luminescence.  
If luminescence is detected, a single colony is then selected from the agar plate 
and transferred to 5mL of LB media along with carbenicillin at a concentration of 
300μg/mL. Cells are then grown for 36-48 at 37°C shaking at 250rpm. From these 
cultures, 50% glycerol stocks of each strain are prepared and stored at -80°C. 
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Section Three: Results 
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PAO1 and PA14 exhibit increased resistance to antimicrobials in synthetic 
CF sputum medium than in standard diagnostic laboratory medium  
Results from minimum inhibitory concentration (MIC) assays revealed that PAO1 and 
PA14 were significantly more resistant to antibiotics when cultured in synthetic CF 
sputum media. This was consistent for all three time points (0, 30, and 60 minutes) and 
all three antibiotics (tobramycin, gentamicin, and polymyxin B).  
Both PAO1 and PA14 were most susceptible to polymyxin B. It is currently the 
last line drug prescribed to patients infected with Pseudomonas aeruginosa, meaning that 
it is only administered after all other treatments have failed. Doctors do this partly in 
order to prevent the bacteria from developing resistance to the antibiotic, however this is 
not the only reason. Though it is extremely effective and fast-acting against the bacteria, 
it is also quite toxic to the human patient.  
On average, at the lowest concentration of antibiotic (4.88e-4 μg/mL), the number 
of viable cells of PAO1 grown in MHB was reduced to about 52.6% after 60 minutes 
(Figure 1). By contrast, PAO1 grown in SCFM2 subjected to the same concentration of 
polymyxin B showed no significant reduction. For a similar killing of PAO1 in the 
SCFM2, the concentration of this antibiotic must be increased eightfold. To reduce the 
bacterial load significantly of PAO1 by the 60 minute time point, a higher concentration 
of polymyxin B is necessary for cells grown in SCFM2 than in MHB. The concentration 
for almost complete cell death in MHB was 0.0078μg/mL at the latest time point, 
compared to 0.0313μg/mL in SCFM2.  
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PA14 was also susceptible to polymyxin B. In MHB, the population of PA14 was 
nearly eradicated at the initial time point at an antibiotic concentration of 0.0078μg/mL. 
By contrast, when PA14 was grown in SCFM2, the same concentration of polymyxin B 
only reduced the population by about 5%. At the initial time point, even the highest 
concentration of this antibiotic was not able to eradicate the population when it was 
grown in SCFM2. Nearly complete killing of PA14 by polymyxin B was achieved in 
SCFM2 after 30 minutes at a concentration of 0.125μg/mL, the second highest 
concentration that was used. By contrast, PA14 grown in MHB was almost completely 
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Figure 1 | PAO1 treated with polymyxin B exhibited higher levels of resistance in 
SCFM2 than in MHB. Increasing concentrations of Polymyxin B significantly impacted 
effected PAO1 growth in MHB compared to cells grown in SCFM2. At 60 minutes, 
differences in the percentages of remaining viable cells were significant at concentrations 
3.91e-3μg/mL (p < 0.0001), 1.95e-3μg/mL (p < 0.0001), 9.77e-4 μg/mL (p < 0.0001), and 
4.88e-4μg/mL (p < 0.0001) as determined by an unpaired t-test. Error bars represent standard 
error of the mean. (n=3) 
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reduced at the 30 minute time point at a concentration of 0.0156μg/mL, 3 times lower 
than was necessary in SCFM2. After 60 minutes, the lowest concentration of polymyxin 
B used was able to reduce the number of viable cells grown in MH by 70%. When 
subjected to the same concentration of polymyxin B, cells grown in SCFM2 experienced 
no significant killing.  
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 Both strains were also exposed to tobramycin. Overall, tobramycin killed that 
bacteria much more slowly than polymyxin B, and the speed of killing varied depending 
on the media in which the bacteria were grown. For instance, when the population of 
PA14 that was grown in MHB was exposed to a tobramycin concentration of 
0.125μg/mL, it was reduced to 50.898% of its original size after 30 minutes. By contrast, 
when exposed to the same concentration of tobramycin, the population of cells grown in 
SCFM2 was only reduced by 9.582% after 30 minutes. Complete killing of PA14 via 
tobramycin did not occur at any concentration of tobramycin in either media, although 
PA14 was significantly more resistant in SCFM2 than in MHB. At the 60 minute time 
point, PA14 grown in MH media was reduced to 45.6171% of its original population size 
when exposed to a tobramycin concentration of 0.0156μg/mL. A similar amount of 
killing (population reduction of 48.0873% compared to original size) in SCFM2 was 
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Fig 2 | PA14 treated with polymyxin B was 
significantly more resistant in SCFM2 than 
in MHB. a-c. At the initial time point (a), 
differences in cell viability at concentrations 
3.91e-3μg/mL to 4.88e-4 were significant as 
demonstrated by an unpaired t test (p < 
0.0001). At the 60 minute time point (c), 
differences in cell viability at concentrations 
3.91e-3μg/mL (p= 0.0058), 1.95e-3μg/mL (p= 
0.0110), and 9.77e-4μg/mL (p= 0.0435) were 
significant as demonstrated by an unpaired t 
test. Error bars represent standard error of the 
mean. (n=3) 
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achieved at 60 minutes at a tobramycin concentration of 0.06250μg/mL, four times 
higher than was necessary in MH media. 
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Figure 3 | PA14 grown in SCFM2 was 
more resistant to tobramycin than cells 
grown in MHB. The effects of the 
antibiotic were not prevalent in the 
earliest time point (a). At the 30 minute 
time point (b), the antibiotic had some 
effect, but the differences between the 
two media were not significant. At the 60 
minute time point (c) differences were 
significant at concentrations 7.81e-3 
μg/mL (p= 0.0015) and 3.91e-3μg/mL 
(p=0.0005), as shown by an unpaired t 
test. Error bars represent standard error. 
(n=3) 
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 Laboratory and clinical strains of P. aeruginosa exhibit different antibiotic 
susceptibility profiles dependent on the type of solid media used 
Disk diffusion assays on Muller-Hinton agar (MHA) and SCFM2 agar were conducted 
using 10 different strains of P. aeruginosa and three clinically relevant antibiotics, 
tobramycin, gentamicin, and polymyxin B. The results from this assay indicated that all 
strains had differing susceptibility profiles when tested on different media. While some of 
the strains were more resistant to all antibiotics on SCFM2 agar, this was not always the 
case. 
 The disk diffusion assays for PAO1 and PA14 yielded analogous results to the 
MIC assays conducted in liquid media. For tobramycin, the zone of inhibition for PAO1 
was 0.67cm greater in diameter in MHA than it was in SCFM2 agar. Via the percent 
increase formula, the diameter of the zone of inhibition was 27.92% greater in the 
Muller-Hinton media than in the SCFM2 agar. Gentamicin produced a zone of inhibition 
that was 0.87cm greater in MHA than in SCFM2 agar. The diameter was thus 45.79% 
greater in MHA than in SCFM2 agar. Polymyxin B yielded similar results, with a 
diameter that was 1.00cm larger and 20.00% greater in MHA than in SCFM2 agar. 
 PA14 was less resistant to tobramycin and gentamicin than PAO1, though both 
strains showed similar levels of susceptibility to polymyxin B. Like PAO1, PA14 showed 
increased levels of resistance—demonstrated by a smaller zone of inhibition—on SCFM2 
agar than on MHA. When tobramycin disks were applied, the zone of inhibition was 
0.70cm wider and 23.33% greater on MHA than on SCFM2 agar. Gentamicin produced a 
kill zone that was 0.67cm wider and 24.10% greater on MHA than on SCFM2 agar. For 
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polymyxin B, the kill zone in MHA was 1.31cm wider and 150.57% greater than it was 
in SCFM2 agar. 
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Figure 4 | PAO1 shows heightened 
resistance to all tested antibiotics in 
SCFM2 agar compared to MHA. An 
unpaired t test demonstrated differences 
in killing for all three antibiotics were 
significant (p = 0.0001). Zone of 
inhibition on MHA represented by 
orange bars and SCFM2 are 
represented by the blue bars. Error 
bars represent standard error of the 
mean. (n=3) 
Figure 5 | PA14 shows heightened 
resistance to all tested antibiotics in 
SCFM2 agar compared to MHA. 
Results of an unpaired t test showed 
significance in the differences in killing 
of tobramycin (p = 0.0001), gentamicin 
(p = 0.0066), and polymyxin B (p 
=0.0038). Zone of inhibition on MHA 
represented by orange bars and SCFM2 
are represented by the blue bars. Error 
bars represent standard error of the 
mean. (n=3) 
Figure 6 | Examples of disk 
diffusion assays performed on 
PA14 and PAO1 on SCFM2 and 
MHA. Measurements of the 
diameters of the kill zones were 
taken 24 hours after antibiotic disks 
were added. Experiments were 
replicated 3 times.  
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The clinical strains SED4, SED6, SED9, SED20, SED21—which were all 
isolated from a single patient—showed very different antimicrobial susceptibility profiles 
than the lab strains PA14 and PAO1. Although PA14 and PAO1 were more susceptible to 
all of the three antibiotics in the clinical diagnostic media, these strains did not mirror this 
pattern. All five strains were more susceptible to tobramycin in the SCFM2 agar than 
they were in the MHA. Additionally, these strains were unaffected by gentamicin in the 
MHA. However, when gentamicin disks were applied to these strains grown on SCFM2 
agar, they were all susceptible to a similar degree. Most of the strains were more 
susceptible to polymyxin B in the MHA compared to the SCFM2 agar. The exception to 
this was strain SED21, which showed relatively equal levels of susceptibility in both 
types of media.  
The British Society for Antimicrobial Chemotherapy (BSAC), sets the standards 
by which bacteria are classified as either resistant or susceptible to antimicrobials in the 
United Kingdom. As clinical isolates originated from and were initially characterized in 
the UK (Darch et al. 2015), we decided to continue to use these susceptibility 
‘breakpoints’. According to the BSAC standards for susceptibility to tobramycin, all five 
of these strains would be classified as susceptible to tobramycin when tested on MH, but 
resistant when tested on SCFM2. 
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Figure 7 | Clinical strains SED4, SED6, SED9, SED 20, SED21 showed statistically 
significant different responses to tobramycin and polymyxin B. In SCFM2, SED4 was 
significantly more resistant to tobramycin (p = 0.0030) and less resistant to polymyxin B (p 
= 0.0418) as demonstrated by an unpaired t test. In the same medium, SED6 was 
significantly more resistant to tobramycin (p = 0.0001) and less resistant to polymyxin B (p 
= 0.0015) as demonstrated by an unpaired t test. Similarly, SED9 was significantly more 
resistant to tobramycin (p = 0.0001) and less resistant to polymyxin B (p = 0.0298) as 
demonstrated by an unpaired t test. Additionally, SED20 was significantly more resistant 
to tobramycin (p = 0.0001) and less resistant to polymyxin B (p = 0.0456) as demonstrated 
by an unpaired t test. Lastly, an unpaired t test showed that SED21 is significantly more 
resistant to tobramycin in SCFM2 (p = 0.0001). Zone of inhibition on MHA represented by 
orange bars and SCFM2 are represented by the blue bars. Error bars represent standard 
error of the mean. (n=3) 
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Three additional clinical strains—C2773C, C1913C, C3881C—were analyzed via 
disk diffusion assays. These clinical strains were isolated from three different patients 
and exhibit a mucoid phenotype, unlike the other seven strains that were tested. Like 
PAO1 and PA14, strains C1913C and C3881C were more resistant to most of the 
antibiotics when grown on SCFM2 agar than on MHA. According to an unpaired t test, 
strain C1913C did not show significantly higher levels of resistance to tobramycin on 
either growth medium (p = 0.0562). However, unlike the five clinical strains previously 
described, this strain was susceptible to gentamicin. When disks treated with this 
antibiotic were placed on C1913C grown on MHA, the zone of inhibition was 0.29cm 
wider and 15.96% greater than cells grown on SCFM2 agar. As expected, this strain was 
also susceptible to polymyxin B. When subjected to polymyxin B, C1913C grown on 
MHA had zones of inhibition that were 0.49cm wider and 45.54% greater than those 
produced around cells grown on SCFM2.  
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Figure 7 | Clinical strains SED4, 
SED6, SED9, SED20, and SED21 
showed varying levels of resistance to 
the three antibiotics. Standard error of 
the mean was calculated and is denoted 
by the error bars. All strains were 
resistant to gentamicin in MHA (SEM 
± 0). SED21 showed relatively equal 
levels of susceptibility to polymyxin B 
in SCFM2 (SEM ± 0.1093) and in 
MHA (SEM ± 0.1600). Zone of 
inhibition on MHA represented by 
orange bars and SCFM2 are 
represented by the blue bars. (n=3) 
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While strain C3881C showed fairly similar levels of susceptibility to these 
antibiotics on both media, strain C2773C had a completely different susceptibility profile. 
This strain was more susceptible to polymyxin B when the cells were grown on MHA 
than on SCFM2 agar. Cells that were tested on MHA had a zone of inhibition that was 
0.67cm wider and 67.60% greater than those grown on SCFM2 agar. An unpaired t test 
demonstrated that this difference was significant (p=0.0001). Strain C2773C did not 
show significantly different responses to tobramycin or gentamicin depending on the 
growth medium in which it was cultured. 
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Figure 8 | Clinical strains C3881C, 
C1913C, and C2773C showed different 
susceptibility to some of the antibiotics 
depending on the medium the cells were 
tested in. As indicated by an unpaired t test, 
strain C3881C was significantly more 
resistant to tobramycin (p= 0.0192), 
gentamicin (p=0.0023), and polymyxin B 
(p=0.0001) in SCFM2 compared to MHA. 
In SCFM2, strain C1913C was only 
significantly more resistant to gentamicin 
(p= 0.0286) and polymyxin B (p= 0.0001). 
Strain C2773C was only significantly more 
resistant to polymyxin B (p= 0.0001). Zone 
of inhibition on MHA represented by 
orange bars and SCFM2 are represented by 
the blue bars. Error bars represent standard 
error of the mean. (n=3) 
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PA14 shows different levels of resistance in modified synthetic sputum 
media, standard synthetic sputum media, and clinical diagnostic media 
SCFM2 is a chemically defined medium, meaning that components are known and can be 
readily added and subtracted during media preparation. In order to determine which 
components in SCFM2 may play a role in the resistance of PA14 to antibiotics compared 
to MH media, PA14 was tested in SCFM2 without sputum and SCFM2 without DNA. 
The results indicated that mucin was important for resistance to all three antibiotics, 
because when mucin was removed PA14 was more susceptible. In SCFM2 without DNA, 
PA14 was more susceptible to tobramycin and gentamicin, but not polymyxin B.  
 When mucin is removed, PA14 are significantly less resistant to tobramycin 
(Figure 10a) at concentrations 1.95e-3 μg/mL (p<0.0001), 3.91e-3μg/mL (p<0.0001), 
and 7.81e-3μg/mL (p<0.0001). The removal of mucin also impacted PA14 survival, as 
Figure 9 | Examples of disk 
diffusion assays performed 
on strains C1913C, C2773C, 
and C3881C. Measurements of 
the diameters of the kill zones 
were taken 24 hours after 
antibiotic disks were added. 
Experiments were replicated 3 
times. 
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measured by luminescence, when treated with gentamicin (Figure 10b). PA14 was 
significantly less resistant to gentamicin at concentrations 1.95e-3 μg/mL (p<0.0001), 
3.91e-3μg/mL (p<0.0001), and 7.81e-3μg/mL (p<0.0001). PA14 was also more 
susceptible to polymyxin B in SCFM2 without mucin (Figure 10c). This was observed at 
concentrations of 1.95e-3 μg/mL (p<0.0001), 3.91e-3μg/mL (p=0.0005), and 7.81e-
3μg/mL (p=0.0054). 
 The removal of DNA also had an impact on PA14 survival when treated with 
tobramycin (Figure 10a) and polymyxin B (Figure 10c). When DNA was removed, 
PA14 was significantly less resistant to tobramycin at concentrations 3.91e-3μg/mL 
(p=0.0287) and 7.81e-3μg/mL (p=0.0217) and 1.56e-2μg/mL (p= 0.0056). Removal of 
DNA did not have a significant impact on the survival of PA14 treated with gentamicin 
(Figure 10b). However, removing DNA did have a significant on the survival of PA14 
treated with polymyxin B. Without DNA, PA14 was significantly more susceptible to 
polymyxin B at concentrations 1.95e-3μg/mL (p=0.0028) and 3.91e-3μg/mL (p=0.0110). 
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Figure 10 | The removal of mucin or 
DNA from SCFM2 influences the 
susceptibility of PA14 to tobramycin, 
gentamicin, and polymyxin B. 
Removing mucin significantly 
increased PA14 susceptibility to all 
three antibiotics, as demonstrated by an 
unpaired t test. Removing mucin had 
varied effects on PA14 response to 
antibiotics. After removing DNA, 
PA14 was less resistant to tobramycin, 
had no significant change in resistance 
to gentamicin, and became more 
resistant to polymyxin B at certain 
concentrations. Error bars represent the 
standard error of the mean. (n=3) 
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Section Four: Discussion 
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The goal of the study was to determine if testing the susceptibility of P. 
aeruginosa to different antibiotics in an environment that more closely recapitulates the 
CF lung would provide different results than tests conducted in nutritionally rich media 
used by diagnostic labs. The pathogen was evaluated using synthetic sputum media 
(SCFM2), which is nutritionally and physically similar to real CF sputum (Palmer et al., 
2007). As such, it is known that the fitness requirements for growth of P. aeruginosa in 
this medium are nearly identical to real CF sputum (Turner et al., 2015). Ten different 
strains of P. aeruginosa were evaluated in SCFM2 and MH media, and the results showed 
that the pathogen demonstrated different levels of resistance to antibiotics depending on 
the media in which it was evaluated. 
The use of SCFM2 in this manner is a novel, in vitro approach to evaluating the 
susceptibility of P. aeruginosa to antibiotics. Ideally, the utilization of SCFM2 in a 
diagnostic, clinical setting could help physicians to select more precise, individualized 
treatments for specific strains isolated from patients. In this study, it has demonstrated 
that different strains of P. aeruginosa respond differently to antibiotics depending on the 
growth medium in which the cells are cultured.  
Previous studies on P. aeruginosa susceptibility to antibiotics have shown that 
there are a number of ways in which this bacterium is able to thwart antibiotic therapies. 
One key attribute is the ability of P. aeruginosa to form aggregates, and this has been 
demonstrated specifically in the CF lung (Kragh et al., 2016). Aggregation has previously 
been correlated with increased levels of antibiotic resistance (Connell, Wessel, 2012), 
although the underlying mechanisms behind this are not well understood. One theory lies 
in the fact that wildtype and some clinical strains of P. aeruginosa are known to produce 
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exopolysaccharides when aggregated, which are known to play a key role in protection 
from environmental disturbances, such as phage which target P. aeruginosa (Darch et al., 
2017). It is possible that these exopolysaccharides could also play a key role in antibiotic 
resistance.  
The minimum inhibitory concentration (MIC) assays revealed that strains PAO1 
and PA14 were more resistant to three clinically relevant antibiotics in the synthetic 
sputum medium than in rich, MH medium. Since studies have shown that P. aeruginosa 
behaves similarly in SCFM2 to authentic CF lung sputum (Palmer et al., 2007; Turner et 
al., 2015), these results indicate that this pathogen could exhibit higher levels of 
resistance to antibiotics than current diagnostic testing techniques reveal. Therefore, in 
order to more accurately evaluate the antimicrobial susceptibility profile of P. 
aeruginosa, SCFM2 presents an alternative culture medium for the testing of isolates, 
rather than in rich media, such as MHB. 
This study also highlights a role for mucin in the ability of P. aeruginosa to form 
aggregates, and/or protect aggregates from antibiotic treatment. On the MIC conducted in 
liquid SCFM2 which lacked mucin, P. aeruginosa  was significantly more susceptible to 
all antibiotics. This indicates that mucin could function as a scaffold, facilitating 
aggregate and biofilm formation, or alternatively may act as a ‘sink’ for antibiotics, 
binding those that are freely available in the extracellular environment. In turn this would 
reduce their ability to enter a bacterial cell.. 
Disk diffusion assays were performed on ten different strains of P. aeruginosa. 
Like the MIC assays, PAO1 and PA14 showed higher levels of resistance to all three 
antibiotics on SCFM2 agar than on MHA. However, when this test was conducted on 
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eight clinical strains of P. aeruginosa, this was not always the case. The results from the 
disk diffusion assay showed that strains C2773C, SED4, SED6, SED9, SED20 and 
SED21 were more less susceptible to tobramycin and gentamicin on the MHA than on 
the SCFM2 agar. This indicates that assays conducted on rich media would produce 
results indicating that the bacteria are far more resistant to antibiotics than they actually 
would be in the patient’s lungs. For instance, for strains SED4, SED6, SED9, SED20, and 
SED21, tests ran on rich media would show that a patient colonized with any of these 
strains could not be treated using gentamicin. However, when tested on SCFM2 agar, the 
tests reveal that this might not be the case.  
In future experiments, MIC assays will be conducted on the eight clinical strains 
to ensure that the disk diffusion assays yield similar results to tests conducted in liquid 
media. These strains will be transformed with a plasmid carrying a light reporter, so that 
cell survival can be measured by the levels of light output. The strains can then be 
evaluated using the exact same protocol by which PAO1 and PA14 were tested. 
The results of this study indicate that P. aeruginosa can have different levels of 
antimicrobial susceptibility in patients’ lungs than in rich media used by diagnostic labs. 
Due to the level of severity that infections from P. aeruginosa can cause in the lungs of 
patients with Cystic Fibrosis, it is essential that improvements be made to the current 
methods used to evaluate the antimicrobial susceptibility of this pathogen. Prescribing 
ineffective antibiotics can lead to increased levels of resistance, making these infections 
almost impossible to remediate. However, it is known that with prompt, aggressive 
treatment, it is not impossible to eradicate the pathogen before it can cause serious harm 
to the patient (Frederiksen et al., 1997). This study shows that a small change to current 
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diagnostic methodology—changing the medium in which P. aeruginosa is evaluated—
has the potential to provide CF patients with effective, personalized antibiotic therapies. 
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